TGF Beta1 Expression Correlates with Survival and Tumor Aggressiveness of Prostate Cancer (Q41485074)

1 October 2017

title

TGF Beta1 Expression Correlates with Survival and Tumor Aggressiveness of Prostate Cancer (English)

1 reference

1 October 2017

Chun-Te Wu

1

1 reference

1 October 2017

Ying-Hsu Chang

2

1 reference

1 October 2017

Wei-Yu Lin

3

1 reference

1 October 2017

Wen-Cheng Chen

4

1 reference

1 October 2017

Miao-Fen Chen

5

1 reference

1 October 2017

language of work or name

1 reference

14 August 2015

1 reference

Annals of Surgical Oncology

1 October 2017

published in

1 reference

1 October 2017

volume

22 Suppl 3

1 reference

1 October 2017

page(s)

S1587-93

1 reference

Screening and prostate-cancer mortality in a randomized European study

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Interleukin-6: a candidate mediator of human prostate cancer morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-β signalling and its role in cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-β signaling and epithelial-mesenchymal transition in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

STAT3 mediates TGF-β1-induced TWIST1 expression and prostate cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Suppression, subversion and escape: the role of regulatory T cells in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

The role of IL-6 in the radiation response of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Non-Smad pathways in TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Significance of the TGF-β1/IL-6 axis in oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Differentiation and function of Foxp3(+) effector regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Molecular pathways: targeting the TGF-β pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Epithelial-mesenchymal transitions in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

What are regulatory T cells (Treg) regulating in cancer and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-015-4804-9

10.1245/S10434-015-4804-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 October 2017

1000931386

0 references

1 reference